Shares of SAGE Therapeutics Inc (NASDAQ:SAGE) have earned an average recommendation of “Buy” from the eleven analysts that are presently covering the company. Three analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $82.30.
SAGE has been the subject of a number of research analyst reports. JPMorgan Chase & Co. reiterated a “buy” rating on shares of SAGE Therapeutics in a research note on Wednesday, January 11th. BMO Capital Markets set a $68.00 price target on SAGE Therapeutics and gave the company a “buy” rating in a research note on Monday, February 13th. Cowen and Company reiterated a “buy” rating and issued a $95.00 price target on shares of SAGE Therapeutics in a research note on Monday, February 13th. Chardan Capital upgraded SAGE Therapeutics from a “sell” rating to a “neutral” rating and set a $60.00 price target for the company in a research note on Tuesday, February 14th. Finally, HC Wainwright cut SAGE Therapeutics from a “buy” rating to a “neutral” rating and increased their price target for the company from $56.00 to $76.00 in a research note on Wednesday, February 22nd.
COPYRIGHT VIOLATION NOTICE: This report was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.chaffeybreeze.com/2017/04/20/sage-therapeutics-inc-sage-receives-80-30-average-target-price-from-analysts-updated-updated.html.
Shares of SAGE Therapeutics (NASDAQ:SAGE) traded up 1.99% on Tuesday, hitting $71.67. 193,391 shares of the stock were exchanged. The company has a 50 day moving average of $68.17 and a 200 day moving average of $54.38. SAGE Therapeutics has a 52-week low of $26.55 and a 52-week high of $74.34. The company’s market cap is $2.67 billion. SAGE Therapeutics also saw some unusual options trading on Monday. Stock traders bought 8,255 call options on the company. This represents an increase of 1,102% compared to the typical volume of 687 call options.
SAGE Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Thursday, February 23rd. The biopharmaceutical company reported ($1.50) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by $0.33. Equities research analysts forecast that SAGE Therapeutics will post ($6.82) earnings per share for the current year.
Several hedge funds and other institutional investors have recently made changes to their positions in SAGE. Fernwood Investment Management LLC purchased a new position in shares of SAGE Therapeutics during the third quarter valued at about $241,000. SG Americas Securities LLC bought a new stake in SAGE Therapeutics during the third quarter valued at approximately $246,000. Sei Investments Co. raised its stake in SAGE Therapeutics by 2,336.8% in the third quarter. Sei Investments Co. now owns 5,702 shares of the biopharmaceutical company’s stock valued at $263,000 after buying an additional 5,468 shares during the period. WFG Advisors LP raised its stake in SAGE Therapeutics by 5,680.8% in the fourth quarter. WFG Advisors LP now owns 9,018 shares of the biopharmaceutical company’s stock valued at $323,000 after buying an additional 8,862 shares during the period. Finally, Denver Investment Advisors LLC bought a new stake in SAGE Therapeutics during the fourth quarter valued at approximately $338,000. Hedge funds and other institutional investors own 99.92% of the company’s stock.
About SAGE Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for SAGE Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.